MAP4K4 and lung adenocarcinoma: Furthermore, In EGFR-mutated and erlotinib-treated lung adenocarcinoma cell lines, downregulation of MAP4K4 prevented ERK reactivation, suggesting that MAP4K4 is critical for maintaining tumor growth (20).